Previous 10 | Next 10 |
Delcath Systems Closes Private Placement of $5.0 Million PR Newswire NEW YORK , July 20, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems ( NASDAQ: DCTH ) entered into a securities purchase agreement with certain accredited investors for a private placement transaction. It will issue and sell 690,954 shares at $3.98/share, 566,761 pre-funded warrants to purchase at a price per pre-funded...
Delcath Systems Announces Private Placement of $5.0 Million PR Newswire NEW YORK , July 18, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liv...
Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...
Buying Penny Stocks on June 7th? Here’s What You Need to Know If you’re looking for penny stocks to buy today, there are quite a lot to choose from. But, it all depends on what your investing style is and how to take advantage of that. This involves doing research and cons...
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival currently is 22.4 months ...
Today, we revisit oncology medical device concern Delcath Systems Inc. for the first time since last summer. The company is on the verge of a potentially game-changing FDA approval. A full investment analysis follows in the paragraphs below. For further details see: Delc...
Delcath Systems Ltd. (DCTH) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dias - Vice President of Finance Conference Call Participants Marie Thibault - BTIG Scott Henry - Roth Capi...
Delcath Systems press release (NASDAQ:DCTH): Q1 GAAP EPS of -$1.00 misses by $0.12. Revenue of $0.38M (flat Y/Y) beats by $0.07M. On March 31, 2022, the Company had cash, cash equivalents and restricted cash totaling $20.5 million, as compared to cash, cash equivalents and restricted cash tot...
NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022. ...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...